- Home
- LCID vs RARE Comparison
LCID vs RARE Comparison
Compare LCID & RARE Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- LCID
- RARE
- Stock Information
- Founded
- LCID 2007
- RARE 2010
- Country
- LCID United States
- RARE United States
- Employees
- LCID N/A
- RARE N/A
- Industry
- LCID Auto Manufacturing
- RARE Biotechnology: Pharmaceutical Preparations
- Sector
- LCID Consumer Discretionary
- RARE Health Care
- Exchange
- LCID Nasdaq
- RARE Nasdaq
- Market Cap
- LCID 5.8B
- RARE 5.2B
- IPO Year
- LCID N/A
- RARE 2014
- Fundamental
- Price
- LCID $2.01
- RARE $44.75
- Analyst Decision
- LCID Hold
- RARE Strong Buy
- Analyst Count
- LCID 10
- RARE 14
- Target Price
- LCID $3.43
- RARE $86.79
- AVG Volume (30 Days)
- LCID 66.1M
- RARE 900.1K
- Earning Date
- LCID 11-07-2024
- RARE 11-05-2024
- Dividend Yield
- LCID N/A
- RARE N/A
- EPS Growth
- LCID N/A
- RARE N/A
- EPS
- LCID N/A
- RARE N/A
- Revenue
- LCID $730,510,000.00
- RARE $522,745,000.00
- Revenue This Year
- LCID $40.55
- RARE $27.29
- Revenue Next Year
- LCID $96.14
- RARE $18.30
- P/E Ratio
- LCID N/A
- RARE N/A
- Revenue Growth
- LCID 4.98
- RARE 27.44
- 52 Week Low
- LCID $1.93
- RARE $37.02
- 52 Week High
- LCID $5.31
- RARE $60.37
- Technical
- Relative Strength Index (RSI)
- LCID 28.13
- RARE 23.47
- Support Level
- LCID $2.12
- RARE $47.73
- Resistance Level
- LCID $2.33
- RARE $53.04
- Average True Range (ATR)
- LCID 0.15
- RARE 2.00
- MACD
- LCID 0.01
- RARE -0.57
- Stochastic Oscillator
- LCID 12.90
- RARE 2.46
About LCID Lucid Group Inc.
Lucid Group Inc is a technology and automotive company. It develops the next generation of electric vehicle (EV) technologies. It is a vertically integrated company that designs, engineers, and builds electric vehicles, EV powertrains, and battery systems in-house using our own equipment and factory.
About RARE Ultragenyx Pharmaceutical Inc.
Ultragenyx Pharmaceutical Inc is a USA-based biopharmaceutical company. It identifies, acquires, develops, and commercializes novel products for the treatment of serious rare and ultra-rare diseases, with a focus on serious, debilitating genetic diseases. The company's medicine portfolio includes Crysvita, Dojolvi, and Mepsevii. Crysvita is indicated for the treatment of X-linked hypophosphatemia (XLH) in adult and pediatric patients 1 year of age and older. Mepsevii is indicated in pediatric and adult patients for the treatment of Mucopolysaccharidosis VII.